MOONLIGHT THERAPEUTICS, INC.

Moonlight Therapeutics is a clinical-stage biotech company focused on developing safe, effective, and patient-friendly treatments for people suffering from food allergies. The company's founders are experts in drug delivery, specifically in designing systems to deliver drugs effectively across the body's barriers. Moonlight's proprietary intradermal skin stamp delivers antigen directly to the skin's immune cells to protect patients from deadly anaphylactic reactions. Their lead program, MOON101, is an allergen-specific immunotherapy delivered via a minimally invasive microneedle skin stamp that introduces peanut antigen to the skin. MOON101 received FDA clearance to proceed to clinical testing and the company initiated its first Phase I clinical trial (SURVEYOR) in June 2026 for peanut-allergic adults and children. Moonlight has received multiple NIH grants to develop its allergen immunotherapy platform and is supported by both public and private funding, including backing from SOSV/IndieBio.